EA200602129A1 - Новое применение пептидных соединений для лечения дискинезии - Google Patents

Новое применение пептидных соединений для лечения дискинезии

Info

Publication number
EA200602129A1
EA200602129A1 EA200602129A EA200602129A EA200602129A1 EA 200602129 A1 EA200602129 A1 EA 200602129A1 EA 200602129 A EA200602129 A EA 200602129A EA 200602129 A EA200602129 A EA 200602129A EA 200602129 A1 EA200602129 A1 EA 200602129A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
diskinesia
peptide compounds
new application
peptide
Prior art date
Application number
EA200602129A
Other languages
English (en)
Inventor
Томас Штёр
Original Assignee
Шварц Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шварц Фарма Аг filed Critical Шварц Фарма Аг
Publication of EA200602129A1 publication Critical patent/EA200602129A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение направлено на применение класса пептидных соединений для лечения первичных или вторичных дискинезий, таких как лекарственная дискинезия.
EA200602129A 2004-05-18 2005-05-17 Новое применение пептидных соединений для лечения дискинезии EA200602129A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57193204P 2004-05-18 2004-05-18
EP04011833A EP1604654A1 (en) 2004-05-18 2004-05-18 Novel use of peptide compounds for treating dyskinesia
PCT/EP2005/005355 WO2005110390A1 (en) 2004-05-18 2005-05-17 Novel use of peptide compounds for treating dyskinesia

Publications (1)

Publication Number Publication Date
EA200602129A1 true EA200602129A1 (ru) 2007-04-27

Family

ID=34925049

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200602129A EA200602129A1 (ru) 2004-05-18 2005-05-17 Новое применение пептидных соединений для лечения дискинезии

Country Status (12)

Country Link
US (1) US7416864B2 (ru)
EP (2) EP1604654A1 (ru)
JP (1) JP4938656B2 (ru)
AT (1) ATE538781T1 (ru)
AU (1) AU2005244440A1 (ru)
BR (1) BRPI0511291A (ru)
CA (1) CA2565051C (ru)
EA (1) EA200602129A1 (ru)
ES (1) ES2380510T3 (ru)
MX (1) MXPA06013300A (ru)
UA (1) UA86808C2 (ru)
WO (1) WO2005110390A1 (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) * 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma
KR20060111524A (ko) * 2003-12-02 2006-10-27 쉬바르츠파르마에이지 펩타이드 화합물들의 중추 신경병증성 통증 치료를 위한신규한 용도
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US8008351B2 (en) * 2004-04-16 2011-08-30 Ucb Pharma Gmbh Methods for prophylaxis or treatment of conditions associated with cortical spreading depression
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EP1781276B1 (en) * 2004-08-27 2010-06-23 UCB Pharma GmbH Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
NZ567108A (en) * 2005-12-20 2011-10-28 Nps Pharma Inc Fluorinated compounds
EA027836B1 (ru) * 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CA2672494A1 (en) * 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
US8933065B2 (en) * 2008-04-01 2015-01-13 The University Of North Carolina At Chapel Hill N-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
US20130251813A1 (en) 2010-12-02 2013-09-26 Ucb Pharma Gmbh Formulation of lacosamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU84891A1 (fr) * 1983-06-30 1985-03-29 Continental Pharma Derives de l'acide 2-aminoacetique,leur preparation et utilisation ainsi que compositions pharmaceutiques contenant ces derives
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
DE69103968T2 (de) * 1990-06-15 1995-03-23 Synthelabo 2-(Aminoalkyl)-5-(arylalkyl)1,3-dioxanderivate, ihre Herstellung und ihre Anwendung in der Therapeutik.
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6048899A (en) * 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
EP0900567A3 (en) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
PT1486206E (pt) * 2000-08-25 2008-01-25 Res Corp Technologies Inc ¿utilizações para aminoácidos anticonvulsivantes para o tratamento de perturbações bipolares¿
DE60120104T2 (de) * 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
PT1243263E (pt) 2001-03-21 2003-03-31 Sanol Arznei Schwarz Gmbh Nova utilizacao de uma classe peptidica de composto para o tratamento de alodinia ou de outros tipos diferentes de dor cronica ou fantasma

Also Published As

Publication number Publication date
CA2565051C (en) 2013-01-22
US20050261204A1 (en) 2005-11-24
JP2007538037A (ja) 2007-12-27
WO2005110390A1 (en) 2005-11-24
JP4938656B2 (ja) 2012-05-23
EP1753414B1 (en) 2011-12-28
BRPI0511291A (pt) 2007-12-04
UA86808C2 (ru) 2009-05-25
ATE538781T1 (de) 2012-01-15
MXPA06013300A (es) 2007-02-22
ES2380510T3 (es) 2012-05-14
EP1753414A1 (en) 2007-02-21
US7416864B2 (en) 2008-08-26
CA2565051A1 (en) 2005-11-24
EP1604654A1 (en) 2005-12-14
AU2005244440A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
EA200602129A1 (ru) Новое применение пептидных соединений для лечения дискинезии
EA201170441A1 (ru) Терапевтические противовирусные пептиды
EA200700225A1 (ru) Аналоги тетрапептида
EA201070247A1 (ru) Ингибиторы протеасом
NO20081636L (no) FAP - inhibitorer
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
NO20074238L (no) Fiksert dosering av HER-antistoffer
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201170872A1 (ru) Ингибиторы протеинкиназы
EA201100037A1 (ru) Органические соединения
EA200601912A1 (ru) Применение пептидных соединений для профилактики и лечения хронической головной боли
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
NO20072092L (no) Sulfonamidforbindelser
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
MX2008007808A (es) Analogos de rifamicina y usos de ellos.
EA201691759A1 (ru) Композиции и способы лечения легочной гипертензии
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
EA201190125A1 (ru) Таблетки для комбинированной терапии
EA200801199A1 (ru) Ингибиторы киназы
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA200700702A1 (ru) Аналоги локсапина и способы их применения
EA200970126A1 (ru) Способ получения прегабалина и его энантиомера
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
CL2007002388A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de hemangiomas o hemangioblastomas.